Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 185,300 shares, a decline of 15.5% from the March 31st total of 219,400 shares. Based on an average daily volume of 354,800 shares, the days-to-cover ratio is currently 0.5 days.
Separately, Zacks Investment Research raised Navidea Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 18th.
In other news, Director Malcolm G. Witter bought 15,000 shares of the stock in a transaction on Wednesday, March 3rd. The shares were bought at an average price of $2.31 per share, with a total value of $34,650.00. Also, Director Malcolm G. Witter purchased 21,500 shares of the business’s stock in a transaction on Monday, March 29th. The shares were purchased at an average price of $2.07 per share, with a total value of $44,505.00. Following the completion of the purchase, the director now owns 47,000 shares in the company, valued at $97,290. The disclosure for this purchase can be found here. Insiders bought 46,500 shares of company stock valued at $95,155 in the last 90 days. Company insiders own 0.49% of the company’s stock.
Navidea Biopharmaceuticals stock traded up $0.01 during mid-day trading on Tuesday, hitting $1.62. The stock had a trading volume of 2,293 shares, compared to its average volume of 327,141. Navidea Biopharmaceuticals has a one year low of $0.85 and a one year high of $5.36. The firm has a market capitalization of $46.28 million, a P/E ratio of -3.10 and a beta of 1.94. The firm’s 50 day moving average is $2.05 and its 200 day moving average is $2.38.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last issued its earnings results on Tuesday, March 23rd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01. Navidea Biopharmaceuticals had a negative return on equity of 372.59% and a negative net margin of 1,310.93%. The company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.60 million. On average, research analysts predict that Navidea Biopharmaceuticals will post -0.47 earnings per share for the current year.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages.
Recommended Story: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.